Literature DB >> 27040353

Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer.

Lingyun Zhang, Lubna Nadeem, Kristin Connor, Guoxiong Xu1.   

Abstract

Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Despite increasing knowledge of ovarian cancer biology and advances in treatment efficacy, the survival rate of patients with EOC has not improved over the past two decades. Patients with an advanced disease often relapse due to the development of chemoresistance. Recent in vivo and in vitro studies have shown insight into the mechanisms of such drug resistance, including a potential role for microRNAs (miRNA, miR) in the process of chemoresistance. In this review, we provide an overview of current therapeutic targets of miRNA-associated chemoresistance in EOC and discuss potential therapeutic values and molecular mechanisms by which miRNAs influence the development and reversal of chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27040353     DOI: 10.2174/1568009616666160404121105

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  12 in total

Review 1.  Exploiting microRNAs As Cancer Therapeutics.

Authors:  Tamsin Robb; Glen Reid; Cherie Blenkiron
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 2.  Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.

Authors:  Anshika Bakshi; Sandeep C Chaudhary; Mehtab Rana; Craig A Elmets; Mohammad Athar
Journal:  Mol Carcinog       Date:  2017-08-22       Impact factor: 4.784

3.  miR-320 inhibited ovarian cancer oncogenicity via targeting TWIST1 expression.

Authors:  Chunyang Li; Ping Duan; Jianguang Wang; Xiaosheng Lu; Jing Cheng
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.

Authors:  Yang Lin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Oncotarget       Date:  2017-09-30

5.  MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/β-catenin signaling pathway in ovarian cancer.

Authors:  Nan Li; Liang Yang; Yanan Sun; Xiaohua Wu
Journal:  Oncol Lett       Date:  2019-01-14       Impact factor: 2.967

6.  Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1.

Authors:  YinYing Wu; Bo Zhu; Yanli Yan; Shuheng Bai; Haojing Kang; Jiangzhou Zhang; Wen Ma; Ying Gao; Beina Hui; Rong Li; Xiaozhi Zhang; Juan Ren
Journal:  Mol Oncol       Date:  2021-03-19       Impact factor: 6.603

7.  Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer.

Authors:  Daibing Zhou; Lingyun Zhang; Qunbo Lin; Weimin Ren; Guoxiong Xu
Journal:  Data Brief       Date:  2017-05-12

8.  Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer.

Authors:  Xin Qi; Chunjiang Yu; Yi Wang; Yuxin Lin; Bairong Shen
Journal:  Clin Transl Med       Date:  2019-10-29

9.  miRNA-21 inhibition suppresses the human epithelial ovarian cancer by targeting PTEN signal pathway.

Authors:  Baozhen Hao; Jing Zhang
Journal:  Saudi J Biol Sci       Date:  2019-08-09       Impact factor: 4.219

10.  A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.

Authors:  Jinguo Zhang; Wencai Guan; Xiaolin Xu; Fanchen Wang; Xin Li; Guoxiong Xu
Journal:  Oncogene       Date:  2021-06-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.